Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
Schmidkonz C, Kuwert T, Atzinger A, Cordes M, Schett G, Ramming A, Götz T (2022)
Publication Type: Journal article, Review article
Publication year: 2022
Journal
Book Volume: 63
Pages Range: 1786-1792
Journal Issue: 12
DOI: 10.2967/jnumed.122.264205
Abstract
Fibroblast activation protein-α (FAP-α) is a type II transmembrane glycoprotein that is overexpressed in activated fibroblasts such as those in the stroma of tumors or in the fibrotic processes accompanying various benign diseases. The recent development and clinical implementation of radiolabeled quinolone-based tracers suitable for PET that act as FAP inhibitors (FAPIs) have opened a new perspective in molecular imaging. Although multiple studies have investigated the use of FAPI imaging in cancer, evidence concerning its use in nonmalignant diseases is still scarce. Herein, we provide a comprehensive review of FAPI imaging in nonmalignant diseases to clarify the current and potential role of this class of molecules in nuclear medicine.
Authors with CRIS profile
Christian Schmidkonz
Medizinische Fakultät
Torsten Kuwert
Lehrstuhl für Klinische Nuklearmedizin
Armin Atzinger
Department of Nuclear Medicine
Michael Cordes
Medizinische Fakultät
Georg Schett
Lehrstuhl für Innere Medizin III
Andreas Ramming
Medizinische Fakultät
Involved external institutions
Germany (DE)How to cite
APA:
Schmidkonz, C., Kuwert, T., Atzinger, A., Cordes, M., Schett, G., Ramming, A., & Götz, T. (2022). Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging. Journal of Nuclear Medicine, 63(12), 1786-1792. https://doi.org/10.2967/jnumed.122.264205
MLA:
Schmidkonz, Christian, et al. "Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging." Journal of Nuclear Medicine 63.12 (2022): 1786-1792.
BibTeX: Download